Our Science – Schlom Website
Jeffrey Schlom, Ph.D.
Dr. Schlom conducts research in the areas of tumor immunology, immunotherapy, mechanisms of tumor cell-immune cell interactions, and immune mechanisms. The Laboratory functions as an integrated translational research program with the goal of designing and developing new immunotherapies and immunologic strategies for cancer treatment and prevention. Ongoing studies involve (1) the analysis of basic immunologic mechanisms and principles, (2) the design and development of novel recombinant vaccines, and immune modulators including checkpoint inhibitors, (3) analysis of tumor cell-immune cell interactions, (4) the discovery of antigenic determinants expressed in human cancers as vaccine targets, (5) the development of new animal models that can be employed in preclinical studies to most reflect human vaccine trials, (6) cytokine biology as it integrates with cancer immunotherapy, (7) the development of clinical grade vaccines and immunostimulants for use in immunotherapy trials for a range of human cancers, (8) collaborative clinical trials involving recombinant vaccines and vaccine strategies in patients with a range of human cancers, and (9) the development of new immunoassays to define immune responses to vaccines from patients enrolled in vaccine trials.
This page was last updated on 11/19/2013.